(Q46141026)

19 December 2017

title

Prognostic value of estrogen receptor and progesterone receptor status in young Chinese ovarian carcinoma patients (English)

1 reference

19 December 2017

1 reference

Xiao-Yun Yang

1

1 reference

19 December 2017

Ming-Rong Xi

series ordinal

2

1 reference

19 December 2017

Kai-Xuan Yang

series ordinal

3

1 reference

19 December 2017

Hai Yu

series ordinal

4

1 reference

19 December 2017

language of work or name

English

0 references

publication date

29 January 2009

1 reference

19 December 2017

published in

Gynecologic Oncology

1 reference

19 December 2017

volume

113

1 reference

19 December 2017

issue

1

1 reference

19 December 2017

page(s)

99-104

1 reference

19 December 2017

Steroid hormones and cancer: (III) observations from human subjects

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.018

Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.018

Transrepression of estrogen receptor beta signaling by nuclear factor-kappab in ovarian granulosa cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.018

Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.018

Steroid receptors in ovarian carcinoma: immunohistochemical determination may lead to new aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.018

Estrogen receptor expression is a common feature of ovarian borderline tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.018

Absence of estrogen receptor-alpha expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.018

An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.018

Estrogen and progesterone receptors in ovarian epithelial tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.018

Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.018

Estrogen and progesterone receptors in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.018

Progesterone receptor status is a significant prognostic variable of progression-free survival in advanced epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.018

Prognostic factors in early-onset epithelial ovarian cancer: a population-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.018

Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.018

Favorable clinical behavior in young ovarian carcinoma patients: a rationale for conservative surgery?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.018

Epithelial ovarian tumors in the reproductive age group: age is not an independent prognostic factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.018

National survey of ovarian carcinoma XII. Epithelial ovarian malignancies in women less than or equal to 25 years of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.018

Survival and prognostic factors in patients with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.018

Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.018

BRCA1Mutations in a Population-Based Sample of Young Women with Breast Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.018

Differential Contributions ofBRCA1andBRCA2to Early-Onset Breast Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.018

Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.018

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.018

Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.018

Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.018

10.1016/J.YGYNO.2008.12.018

7 January 2021

Identifiers

DOI

1 reference

19 December 2017

PubMed ID

19178934

1 reference

19 December 2017